Real World Evidence on Clinical Outcomes with Aztreonam-Avibactam (ATM-AVI)

Research grant program seeking proposals to assess clinical outcomes associated with ATM-AVI use in real-world clinical settings for adult patients with suspected or documented infections due to aerobic gram-negative organisms (e.g., CRE-MBL, Stenotrophomonas maltophilia).

Overview

• Funding: Up to $50,000 USD per individual project (includes direct costs, institutional overhead capped at 28%, and indirect costs)
• Total available budget: $250,000 USD across all awards
• Maximum project duration: 12 months
• Geographic scope: Countries where ATM-AVI is available (excluding US), including parts of EU, United Kingdom, Middle East, and selected Asia-Pacific markets
• Payment distributed following fully executed agreement, Final Protocol submission, and Documentation of IRB/IEC Approval and Regulatory Approval (if applicable)
• Grants awarded through independent review by Pfizer to support healthcare community's research initiatives

Priority Areas

• Clinical effectiveness with ATM-AVI: Assessing effectiveness outcomes in adult patients with aerobic gram-negative infections
• Safety outcomes with ATM-AVI: Evaluating safety profiles and adverse events in real-world clinical practice
• Microbiological outcomes with ATM-AVI: Studying pathogen response and microbiological clearance
• Health Economic outcomes with ATM-AVI: Economic evaluation in addition to any of the above clinical outcomes
• Special populations: May include immunocompromised patients, solid organ transplant recipients, or haemato-oncological patients

Eligibility & Requirements

• Institution and Principal Investigator must be based in eligible countries (ex-US where ATM-AVI is clinically available)
• Only organizations eligible to receive grants (not individuals or independent medical practice groups)
• If multiple departments/institutions involved, all must have relevant roles with requesting organization having key role
• PI must hold medical or postdoctoral degree (MD, PhD, or equivalent), advanced nursing degree (BSN with MS/PhD), or pharmacy degree
• PI must be employee or contractor of requesting organization
• Requesting organization must be legally able to receive award funding directly from Pfizer Inc. (confirmation prior to application strongly recommended)
• Proposals from institutions already participating in Pfizer-sponsored or funded overlapping ATM-AVI RWE studies may be out of scope
• Proposals involving patients who received ATM-AVI via pre-approval or pre-launch expanded access routes may be out of scope
• Proposals requesting drug compounds (investigational or approved products) will not be accepted
• ISR grant requests cannot be submitted for studies that have already commenced and were not originally supported by Pfizer
• Institutional overhead costs capped at 28% per Pfizer policy
• No funding for capital purchases (infrastructure, equipment, software licenses, technology, or construction)
• Grant awards cannot be used to purchase Pfizer therapeutic agents
• Grantee must enter into written grant agreement with Pfizer; modifications will not be reviewed unless genuine legal conflict exists

Timeline

• RFP Release: March 10, 2026
• Submission Deadline: April 28, 2026 (23:59 EST) - applications submitted after this date will not be reviewed
• Anticipated Grant Award Notification: August 2026
• Anticipated Project Start Date: September 2026
• Anticipated Project End Date: September 2027 or 12 months after start date
• Applicants may be asked for additional clarification during review period
• All applicants will be notified via email

How to Submit:

• Navigate to www.cybergrants.com/pfizer/Research and sign in (first-time users click "Create your password")
• Click "Start A New Research Grant Application" button
• Complete all required sections of online application
• For "Competitive Grant?" select "Yes"
• Select Primary Area of Interest: Infectious Disease - Bacterial - RES
• Select Competitive Grant Program Name: 2026 I&I G ATM-AVI RES
• Upload proposal in Proposal/Protocol field (15-page limit exclusive of references, single-spaced, Calibri 12-point font, 1-inch margins)
• Required proposal sections: Goals and Objectives, Assessment of Need, Target Audience, Project Design and Methods, Innovation, Evaluation and Outcomes, Anticipated Project Timeline, Additional Information, Organization Detail, Budget Detail
• Early-career applicants: Include letter(s) of support from mentor(s) and collaborators
• Budget must be in USD and cannot exceed $50,000 per project
• Required documents: Project Plan or Proposal, Initial Study Protocol
• For technical difficulties with website, click "Technical Questions" link in Cybergrants
• For questions regarding RFP, contact Grant Officer Talita Honorato-Rzeszewicz (Talita.honorato-rzeszewicz@pfizer.com) with subject line "2026 I&I G ATM-AVI RES"

Please note: Full RFP is attached in the "More Information" section of this page. Faculty and researchers interested in applying for these opportunities based on technologies developed or disclosed at Vanderbilt must submit their proposals through the CTTC.